The trading price of Matinas BioPharma Holdings, Inc. (NYSE:MTNB) floating higher at last check on Monday, Feb 22, closing at $1.41, 0.71% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $1.3600 and $1.4300. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 2.78. In examining the 52-week price action we see that the stock hit a 52-week high of $2.22 and a 52-week low of $0.49. Over the past month, the stock has suffered -11.88% in value.
Matinas BioPharma Holdings, Inc., whose market valuation is $281.2 Million at the time of this writing, is expected to release its quarterly earnings report in Apr 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.03 per share this quarter, however they have predicted annual earnings per share of -$0.11 for 2021 and -$0.14 for 2022. It means analysts are expecting annual earnings per share growth of -0.15% this year and 0.27% next year.
On the technical side, indicators suggest MTNB has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
An evaluation of the daily trading volume of Matinas BioPharma Holdings, Inc. (NYSE:MTNB) indicates that the 3-month average is 6.55 Million. However, this figure has declined over the past 10 days to an average of 4.68 Million.
Currently, records show that 199.64 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 7.71% of outstanding shares, whereas institutions hold 23.63%. The stats also highlight that short interest as of January 28, 2021, stood at 15.43 Million shares, resulting in a short ratio of 1.84 at that time. From this, we can conclude that short interest is 7.73% of the company’s total outstanding shares. It is noteworthy that short shares in January were down slightly from the previous month’s figure, which was 16.14 Million. However, since the stock’s price has seen +3.68% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.